0001192482-20-000291.txt : 20200420 0001192482-20-000291.hdr.sgml : 20200420 20200420194231 ACCESSION NUMBER: 0001192482-20-000291 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200417 FILED AS OF DATE: 20200420 DATE AS OF CHANGE: 20200420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENWOOD GERALDINE CENTRAL INDEX KEY: 0001236451 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36329 FILM NUMBER: 20803686 MAIL ADDRESS: STREET 1: 88 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Recro Pharma, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (484) 395-2400 MAIL ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 4/A 1 edgar.xml PRIMARY DOCUMENT X0306 4/A 2020-04-17 2020-04-20 0001588972 Recro Pharma, Inc. REPH 0001236451 HENWOOD GERALDINE C/O RECRO PHARMA, INC. 490 LAPP ROAD MALVERN PA 19355 1 1 0 0 President and CEO Common Stock 2020-04-17 4 M 0 80000 2.47 A 321194 D Common Stock 2020-04-17 4 S 0 80000 8.22 D 241194 D Common Stock 50000 I By: Spouse Employee Stock Option (Right to Buy) 2.47 2020-04-17 4 M 0 80000 0 D 2024-12-16 Common Stock 80000 0 D This amended Form 4 is being filed to reflect an exercise of options that occurred on the same day as the transaction. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.51, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. The shares subject to this option are fully vested and exercisable. /s/ Ryan D. Lake, attorney-in-fact 2020-04-20